Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain
about
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family membersInhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceShepherding AKT and androgen receptor by Ack1 tyrosine kinaseChk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signallingThe evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activityActivated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradationTargeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype.The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancerExpression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational controlThe tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptorsLoss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to HerceptinTargeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signalingDexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytesMig-6 is required for appropriate lung development and to ensure normal adult lung homeostasisMig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formationActivation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli.The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism.microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.Negative regulation of receptor tyrosine kinase signals.MicroRNAs in the Myocyte Enhancer Factor 2 (MEF2)-regulated Gtl2-Dio3 Noncoding RNA Locus Promote Cardiomyocyte Proliferation by Targeting the Transcriptional Coactivator Cited2.ERBB receptor feedback inhibitor 1 regulation of estrogen receptor activity is critical for uterine implantation in mice.Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo.Mig-6 controls EGFR trafficking and suppresses gliomagenesisTargeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease.In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptorGenome wide expression profiling reveals suppression of host defence responses during colonisation by Neisseria meningitides but not N. lactamica.Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetesDecreased Mitogen Inducible Gene 6 (MIG-6) Associated with Symptom Severity in Children with Autism.Amelioration of hypercholesterolemia by an EGFR tyrosine kinase inhibitor in mice with liver-specific knockout of Mig-6.Mig-6 gene knockout induces neointimal hyperplasia in the vascular smooth muscle cell.The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.Gene expression modifications in Wharton's Jelly mesenchymal stem cells promoted by prolonged in vitro culturingNegative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldmiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activationThe regulation of embryo implantation and endometrial decidualization by progesterone receptor signaling.PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cellsLoss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6
P2860
Q21195197-20CBF7A0-E8EA-4DD2-A178-7CEBBD6ECD03Q24301761-8748C545-FB77-4A7D-8E82-A27B3F7FF740Q24308859-4D224BB9-B6AA-48BB-8166-3F7D6C22C917Q24314273-EFD6ECEE-0A69-4D1C-903F-15A4C76FF13CQ24314999-C4E9DBBA-721E-42DB-840D-6B308A154564Q24337716-C51DE3A9-B4FA-4D2F-A417-1B72818474B2Q24539106-25845FA2-4711-4838-AC67-73B7CE5CBBC4Q26770682-E3E816AB-9F14-45AF-9756-E1DCA22D7039Q28201580-376227D6-EE77-4BFD-99CF-5C954FB83D75Q28207839-29428896-1D8E-4C2D-8EA9-FFCED6EE98D8Q28247112-7E4585AB-BD93-40C5-A343-0ADE60782B07Q28573220-530CE25B-4AEC-4FD7-ACA1-DC6244651E22Q28579774-0A6B3FEA-CAA6-430F-8F99-3F60CF5479C0Q28587589-F9585D5D-A379-4D7A-8795-86376408887DQ28590384-162FDC37-666A-40B8-9870-86741C78F817Q30159764-AC5B9E13-726D-47AE-BD3F-DE0814643A5FQ30164215-36916E83-8962-4726-B2B4-550C80FACBBBQ30407637-1C940AA7-8863-446D-A81B-EE393B83247BQ32062430-499A5C1A-D264-4F00-B756-884602E49A64Q33288820-50DBFE5C-0E66-43A3-B485-1C4E30115CD5Q33742326-3FF217C5-090F-4018-ACB4-2C154CB4B4C4Q33765924-53052512-9CEB-47F1-998D-C013DF7E114DQ33859568-3977D24B-9A30-48CB-AF6A-B1A9A5C7A87EQ33920211-DC2F2663-4B2A-463F-AEA6-F37F3B7494B2Q34016590-1D2A6A77-BAE6-4C7C-A544-08A89A8925F0Q34058392-7812E9EB-6EE9-4F39-924E-72327166DD56Q34143192-6E5BD076-68EF-4581-881E-E28D3C7CB993Q34342656-72863AB0-6C1A-4CDC-AD22-75317A477AF2Q34655000-3E96AF83-B01A-4C38-8659-F4BECEA57638Q34773853-5E87DE87-684A-4D86-AD14-7655C2171344Q34918878-2D1308C4-482B-4324-A170-892544D94AB3Q34992991-729CF2E0-8C46-4DED-8F13-EB36D39552F2Q34996130-FDD136F3-0CF9-40E3-8D34-7A493C172F79Q34996775-E7D2C127-28C7-41D4-9791-EB008D2519EFQ35221471-7529DB75-0DA6-4F78-9A68-10BE20A11210Q35667152-62ADDF2E-F113-4AB5-A0CF-D5384871726AQ35764344-8C1E256A-EDD3-4A2B-945A-929CF92D2FCEQ36028210-A85C678E-B890-4B63-B7ED-580A6A820256Q36221780-F0D1B1A8-C82A-4A3E-A6CD-DE2ECB7073C9Q36683851-E01FF39E-3F64-4AF5-B4B4-0AD82DF6FFEF
P2860
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@ast
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@en
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@nl
type
label
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@ast
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@en
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@nl
prefLabel
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@ast
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@en
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@nl
P2093
P2860
P50
P3181
P1476
Inhibition of ErbB-2 mitogenic ...... ds to the ErbB-2 kinase domain
@en
P2093
L Fiorentino
P Benedetti
P2860
P304
P3181
P356
10.1128/MCB.20.20.7735-7750.2000
P407
P577
2000-10-01T00:00:00Z